Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Succession Planning Targeted In Congress As Hamburg Heads For Exit

This article was originally published in The Gray Sheet

Executive Summary

Margaret Hamburg’s departure from commissioner post seems to be proceeding smoothly; proposals in the House 21st Century Cures discussion draft would mandate a similar process always be followed.

You may also be interested in...



'Cures' Innovation Fund Targeted At Some Device Provisions In Latest Bill

FDA officials could draw from $550 million of a new “Innovation Fund” to implement certain 21st Century Cures legislation device reforms, including a breakthrough device program, health IT reforms and other provisions. The latest version of the bill, which newly directs those funds to device sections, is heading to the House floor this week.

FDA Commish Hamburg Gets Fond Farewell

FDA Commissioner Margaret Hamburg said she will step down from the agency after six years in the post. She is being widely praised by lawmakers and industry as an effective bureaucrat who has worked to improve FDA’s regulatory processes and speed the path to market for new products.

FDA’s Acting Chief Scientist Offers Vaccine Continuity As Goodman Departs

Jesse Goodman will become director of Georgetown University’s new Center on Medical Product Access, Safety and Stewardship while Stephen Ostroff steps up as FDA’s Acting Chief Scientist.

Related Content

Topics

UsernamePublicRestriction

Register

MT034515

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel